Palmitoylethanolamide (PEA)
An endogenous fatty acid amide your body already makes in response to tissue damage. One of the better-evidenced pain supplements, and almost nobody has heard of it.
Palmitoylethanolamide (PEA) quick facts
| Suggested dose | 600–1,200 mg daily of MICRONIZED or ultramicronized PEA. Effects typically build over 2–4 weeks. |
| How often | Daily |
| Who it's for | Chronic neuropathic or inflammatory pain, especially where NSAIDs are not an option. |
Solid trial evidence in chronic and neuropathic pain, with a remarkably clean safety profile and essentially no known drug interactions — an unusual combination. Increasing interest in post-viral cognitive symptoms on the glial mechanism. Micronized or ultramicronized forms are what the trials used; the plain form is poorly absorbed enough that the distinction matters.
How Palmitoylethanolamide (PEA) actually works
An endogenous fatty acid amide that acts primarily through PPAR-alpha, downregulating mast-cell degranulation and glial activation. It is not a cannabinoid but it potentiates endocannabinoid signaling by competing for the enzymes that degrade anandamide. The target is neuroinflammation specifically rather than nociception.
Where to get Palmitoylethanolamide (PEA)
Find Palmitoylethanolamide (PEA) on iHerb →The evidence for Palmitoylethanolamide (PEA)
Graded by what exists behind each claim.
✅ Clinically validated
- Meta-analyses of RCTs show clinically meaningful reductions in chronic pain scores, with a number-needed-to-treat around 1.7 in some analyses — a strong figure for any pain intervention.
- Trials support benefit in sciatica, diabetic neuropathy, carpal tunnel and fibromyalgia.
- Adverse event rates are consistently no different from placebo across trials — unusual in the pain literature.
📊 Correlative data
- Occurs naturally in egg yolk, peanuts and soy lecithin, and was first identified because those foods showed anti-inflammatory activity. Levels in human tissue rise at sites of injury and inflammation, which is an observational finding about endogenous production rather than about intake.
🧪 Theoretical / extrapolated benefits
- A PPAR-alpha agonist that downregulates mast cell and glial activation. It also potentiates endocannabinoids indirectly via the 'entourage effect', without binding CB receptors itself.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Palmitoylethanolamide (PEA) actually does
Palmitoylethanolamide is not a drug the body meets for the first time in a capsule. It is a 299-dalton fatty acid amide the body already synthesizes on demand, in the tissue that is being injured, at the moment it is injured. It is made from N-palmitoyl-phosphatidylethanolamine by an N-acyl phosphatidylethanolamine-specific phospholipase D, and it is destroyed by two hydrolases -- fatty acid amide hydrolase and, more selectively, N-acylethanolamine acid amidase Basu 2024. That synthesis-and-destruction pair is the clock this page is about.
The receptor is nuclear, which is why nothing happens in an hour. The best-supported target is peroxisome proliferator-activated receptor alpha, a ligand-activated transcription factor Clayton 2021. Occupying it does not open an ion channel; it changes which genes are transcribed in mast cells, microglia and astrocytes. The read-out is therefore a protein-synthesis read-out, and protein synthesis has a lag measured in days.
The second mechanism is indirect and is often misdescribed. Palmitoylethanolamide does not bind cannabinoid receptors. It competes for the same degrading hydrolases as anandamide, so raising its concentration slows anandamide breakdown -- the entourage effect Basu 2024. This is a competitive-inhibition argument, and competitive inhibition depends on maintaining concentration, not on reaching a peak.
Put those together and the honest mechanism has a schedule attached. A molecule that works by keeping a nuclear receptor occupied and a hydrolase busy is a molecule whose useful variable is time above a threshold, not peak concentration. Meta-analysis of the double-blind randomized trials in chronic pain is consistent with exactly that shape: benefit accumulating over weeks rather than appearing on day one Lang-Illievich 2023.
Cell, rodent, human — and where it stops
This is one of the few supplements on this site whose human evidence is stronger than its mechanistic story, and the transfer problem is a particle size.
What has been measured in people. A systematic review and meta-analysis restricted to double-blind randomized controlled trials pooled palmitoylethanolamide against placebo for chronic pain and found a benefit, with adverse event rates that did not separate from placebo Lang-Illievich 2023. That combination -- an effect with no side-effect signal -- is unusual enough in the pain literature to be worth stating plainly, and it is also the reason to look hard at what the trials actually gave people.
The obstacle is that the molecule is a lipid that barely dissolves. A comparative pharmacokinetic study in male Sprague-Dawley rats gave micronized, water-dispersible and standard palmitoylethanolamide as single oral doses and measured the resulting exposures against each other Mehkri 2025. Particle size and dispersion, not milligrams, decided how much appeared. A capsule of unmicronized powder and a capsule of ultramicronized powder declaring the same 600 mg are not the same experiment.
The rodent step breaks in the usual place and one specific one. Rat single-dose work is an acute exposure study in a fasted animal, and the clinical claim is a multi-week accumulation claim in people who eat Mehkri 2025. Nothing in a single-dose rat curve tells you what four weeks of twice-daily dosing does to tissue concentration.
What would close the gap. A trial that reports plasma palmitoylethanolamide at steady state alongside the pain score, in both a micronized and a non-micronized arm. Formulation work is now moving in that direction -- a phospholipid-based delivery system has been developed specifically to raise solubility and systemic exposure, with clinical outcomes reported alongside it in chronic neuropathic low back pain Khan 2026. Until exposure is reported next to effect, the meta-analytic estimate belongs to an average of formulations rather than to any bottle.
Palmitoylethanolamide (PEA) — which form, and does it matter
Micronization is the whole product decision, and it is the one thing a panel is not required to state. Palmitoylethanolamide is practically insoluble in water. Grinding it to a smaller particle raises dissolution surface area, and the head-to-head rat pharmacokinetic comparison of micronized, water-dispersible and standard material exists precisely because the three behave differently Mehkri 2025. A bottle that says only 'palmitoylethanolamide 600 mg' is silent on the variable that decides the exposure.
The trial-grade descriptors are micronized and ultramicronized. Those words describe a defined particle distribution and they are the descriptors used in the reviewed literature Lang-Illievich 2023 Clayton 2021. A product that does not print one of them has not made the claim, and there is no reason to assume it in the reader's favor.
A third form is now in the literature. Phospholipid-based delivery has been used to raise solubility and systemic exposure Khan 2026, which puts this ingredient on the same road that curcumin and coenzyme Q10 have already traveled: a formulation arms race in which the milligrams on the front of the bottle stop being comparable between brands.
There is no vendor formula filed for this ingredient on this site. supplements_data.BLENDS carries no panel for it, so this page makes no claim about what any specific bottle contains beyond the descriptors above.
What would have to be true, and how you would know it was not
1. The onset prediction, and it is the one that decides whether somebody quits early. A validated pain score at baseline, 2 weeks and 6 weeks on a micronized preparation. Predict little at 2 weeks and a measurable change by 6, because a transcription-factor mechanism does not act acutely Clayton 2021 Lang-Illievich 2023. If a person reports a large change on day two, that is a different mechanism from the one on this page.
2. The formulation prediction. Same daily milligrams, unmicronized for 6 weeks and micronized for 6 weeks, same score. Predict the micronized block wins, because the rat exposure comparison says the material differs Mehkri 2025. If the two blocks tie, the micronization premium is not buying anything in people and this page is wrong about the form.
3. The inflammatory-marker prediction, deliberately unflattering. High-sensitivity C-reactive protein at baseline and 12 weeks. Predict no reliable change, because the proposed action is local mast cell and glial regulation rather than a systemic acute-phase effect Basu 2024. Anyone selling this on a CRP claim is making a promise the mechanism does not support.
4. The washout prediction. Stop for 4 weeks after a responding 12-week block and re-score. Predict a slow return toward baseline rather than an abrupt rebound, because the mechanism is expression-level Clayton 2021. An abrupt rebound within 48 hours would point at something receptor-mediated and fast, which this is not supposed to be.
What nobody has tested yet
Nobody has published a steady-state exposure-response curve in people. The rat comparison gives relative exposure Mehkri 2025 and the meta-analysis gives clinical effect Lang-Illievich 2023. No human study reports plasma concentration and pain score from the same participants.
Nobody knows the right interval. Trials have used once-daily and twice-daily schedules at similar totals, and no study has randomized the split. For a molecule whose argument is time above a threshold, that is the missing experiment.
Nobody has tested it for longer than the trials run. The reviewed program is weeks to months Lang-Illievich 2023. Multi-year daily use of a peroxisome proliferator-activated receptor alpha ligand has not been studied in this population.
And nobody has separated the entourage contribution. Whether the benefit runs through the nuclear receptor, through slowed anandamide hydrolysis, or both, is still argued from mechanism rather than settled by a blocking experiment in people Basu 2024.
Palmitoylethanolamide (PEA) — its own safety story, not its category's
The unusual thing about this product's safety story is that there is very little in it, and the honest way to say that is with the limits attached. The pooled double-blind trials report adverse event rates that do not separate from placebo Lang-Illievich 2023, and mild gastrointestinal upset is the common complaint. That is a real finding and it is a finding about weeks, not decades.
The duration limit is the actual caveat. No trial in the reviewed program runs for years Lang-Illievich 2023 Clayton 2021, so nothing can be said about continuous daily use over a long horizon. That is a gap in the record rather than evidence of harm, and it is the difference worth keeping straight.
The interaction question is open rather than reassuring. No significant drug interactions have been identified in the clinical literature, and the compound is a substrate for hydrolases it shares with the endocannabinoids Basu 2024. Anyone taking a drug that targets fatty acid amide hydrolase should treat that overlap as unstudied rather than as cleared.
Who should be cautious. Pregnancy and breastfeeding are unstudied. Anyone whose pain is new, severe, or accompanied by weakness, fever or weight loss needs a diagnosis before a supplement, because a molecule that reduces a pain score does not remove the reason for the pain. Nothing here is medical advice or a diagnosis, and none of these statements has been evaluated by the Food and Drug Administration.
Sources read for this page
- Lang-Illievich K. Palmitoylethanolamide in the Treatment of Chronic Pain: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials. Nutrients 2023 · PMID 36986081
- Mehkri S. Pharmacokinetics of micronized and water dispersible palmitoylethanolamide in comparison with standard palmitoylethanolamide following single oral administration in male Sprague-Dawley rats. Indian J Pharmacol 2025 · PMID 40686353
- Khan A. Phospholipid-Based Delivery System Optimizes the Solubility and Systemic Exposure of Palmitoylethanolamide and Supports Clinical Benefits in Chronic Neuropathic Low Back Pain. Biomedicines 2026 · PMID 41751279
- Basu D. Palmitoylethanolamide, an endogenous fatty acid amide, and its pleiotropic health benefits: A narrative review. J Biomed Res 2024 · PMID 39433509
- Clayton P. Palmitoylethanolamide: A Natural Compound for Health Management. Int J Mol Sci 2021 · PMID 34069940
How you would know if it worked
There is no blood test for this one. That is not a criticism — it is a fact about the effect, and it changes how you should judge it.
- What to watch: One named pain problem, scored at the same time each day: burning in the feet at night, how far you walk before the sciatic pain starts, how long you can hold a grip before the wrist gives out. Its trials are in specific neuropathic and inflammatory conditions, and a global pain level will not resolve what they measured.
- How long before it means anything: Two to four weeks, building rather than acute. It works through PPAR-alpha and by damping mast cell and glial activation, none of which reports on day one — which is exactly when most bottles get judged and discarded.
- What will fool you: Particle size, which is the whole game. Non-micronized material absorbs poorly and every trial worth citing used micronized or ultramicronized PEA, so an unlabeled bottle that did nothing tested the bottle rather than the molecule. If a label will not say which one it is, it probably is not.
Run it one variable at a time. Starting three things in one week means a result you cannot attribute, which is the same as no result.
Palmitoylethanolamide (PEA) — safety & side effects
- Among the best-tolerated things in this catalog — trials consistently report side-effect rates no different from placebo. Mild GI upset is the only common report.
- No significant drug interactions identified.
- Long-term safety has not been characterized — the trials run weeks to months, not years. That is a real limit on what anyone can tell you about daily use for a decade. That is the only real caveat.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this against it with a pharmacist or doctor — pharmacists are underused and free.
- When to take it, and what to take it with
- Which form actually absorbs
- Who it's worth it for
- Coach Cam's stacks and notes
- Fasted or with food, and when in the day
- Morning or night, and why that window
- Around training, or deliberately away from it
- What it must not share a window with
Everything above is free and stays free. Skool is where it becomes a plan — Palmitoylethanolamide (PEA) in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Palmitoylethanolamide (PEA)
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| TSH (Thyroid-Stimulating Hormone) | Thyroid disease imitates every cognitive complaint there is |
| Vitamin B12 | Deficiency causes fog long before it causes anemia |
| Methylmalonic Acid (MMA) | Catches the deficiency a normal B12 hides |
| Ferritin | Low iron flattens cognition at levels most labs call fine |
| Vitamin D (25-Hydroxy) | Commonly low, cheap to correct, associated with mood |
The Brain Fog & Cognition panel covers these in one order — 12 markers, $233.06 with the discount applied.
Check results you already have → · All 103 markers A–Z
Palmitoylethanolamide (PEA) — frequently asked questions
What is Palmitoylethanolamide (PEA)?
An endogenous fatty acid amide your body already makes in response to tissue damage. One of the better-evidenced pain supplements, and almost nobody has heard of it.
What is the suggested dose of Palmitoylethanolamide (PEA)?
600–1,200 mg daily of MICRONIZED or ultramicronized PEA. Effects typically build over 2–4 weeks. This is a general reference for education only — statements have not been evaluated by the FDA and this is not medical advice.
Where can I find Palmitoylethanolamide (PEA) dosing and the full breakdown?
The suggested dose and the full evidence — clinical, correlative and theoretical — are on this page. What's inside Skool is when to take it, which form actually absorbs, the brand worth buying and Coach Cam's stacks.
Where can I buy Palmitoylethanolamide (PEA)?
Coach Cam sources Palmitoylethanolamide (PEA) from vetted, top-rated brands on iHerb — use the buy link on this page.
Palmitoylethanolamide (PEA) inside a finished plan
One arm of 3 Protocol Blueprints, free to read in full.
What Palmitoylethanolamide (PEA) is used for
Palmitoylethanolamide (PEA) appears under 5 goals in the goal router.
Related Cognitive & Mood supplements
Where this goes next
Palmitoylethanolamide (PEA) is the neuroinflammation arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.